Targeting dendritic cells to drive PDAC immunotherapy response
Alyssa G Weinstein1, David G DeNardo2
1Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA; Cancer Biology Graduate Program, Washington University School of Medicine, St Louis, MO 63110, USA.
Trends in Pharmacological Sciences
|November 7, 2024
Summary
Pancreatic cancer (PDAC) is difficult to treat with immunotherapy. An engineered dendritic cell vaccine (DC1) increased immune cell infiltration, making PDAC more responsive to immunotherapy.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits resistance to immunotherapy.
- This resistance is linked to low tumor antigenicity and insufficient immune cell infiltration, including dendritic cells (DCs) and T cells.
Purpose of the Study:
- To investigate if enhancing dendritic cell (DC) infiltration can overcome immunotherapy resistance in PDAC.
- To evaluate the efficacy of an engineered DC1 vaccine in sensitizing PDAC to immunotherapy.
Main Methods:
- Utilized an engineered DC1 vaccine to promote DC infiltration into PDAC tumors.
- Assessed the impact of increased DC infiltration on the tumor microenvironment and immune response.
Main Results:
- The engineered DC1 vaccine successfully increased the infiltration of DCs into PDAC tumors.
- Enhanced DC infiltration correlated with improved sensitization of PDAC to immunotherapy.
Conclusions:
- Increasing dendritic cell infiltration via an engineered DC1 vaccine is a promising strategy to enhance immunotherapy efficacy in pancreatic cancer.
- This approach may help overcome immunotherapy resistance in PDAC.
